Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

We do not hold a plain-English summary of this study yet. Use the links to the original below for its abstract and findings.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R. A., Klunk, W. E., et al. (2010). 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(10)70043-0

Vancouver

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock RA, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. The Lancet Neurology. 2010. doi:10.1016/s1474-4422(10)70043-0. PMID: 20189881.

BibTeX

@article{rinne2010-20189881,
  author  = {Rinne, Juha O. and Brooks, David James and Rossor, Martin N. and Fox, Nick C. and Bullock, Roger Alan and Klunk, William E. and Mathis, Chester A. and Blennow, Kaj and Barakos, Jerome A. and Okello, Aren and de Liano, Sofia Rodriguez Martinez and Liu, Enchi and Koller, Martin and Gregg, Keith M. and Schenk, Dale and Black, Ronald S. and Grundman, Michael},
  title   = {{11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study}},
  journal = {The Lancet Neurology},
  year    = {2010},
  doi     = {10.1016/s1474-4422(10)70043-0},
  pmid    = {20189881},
  url     = {https://doi.org/10.1016/s1474-4422(10)70043-0}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 17 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Why it matters

A phase 2, double-blind, placebo-controlled, ascending-dose study used 11C-PiB PET scans to assess change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab.

How this study scored 55/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence left out, no data; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 1 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 6 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 52 of the 95 points it could be judged on, which is 55 of 100. Total 55 of 100.52 of the 95 points we could judge = 55 of 100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported and studied in people because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 52 of the 95 points we could judge it on, which is 55 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (The Lancet Neurology)
Journal's citation record 3 / 4 The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence — / 5 No evidence rating recorded — left out of this score
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2010 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 1 / 2 Blinded or placebo-controlled (as stated in the record)
Times cited 6 / 7 Cited 702 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 39.0 citations a year over 18 year(s) since 2010
Impact for its field and year 6 / 6 Cited 57.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 30 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Michael Grundman: h-index 59 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 14 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 20189881)
Free to read 0 / 2 Behind a paywall — scores zero
Points 52 / 95 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 52 of the 95 points we could judge it on is 55 out of 100.
Total 55 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →